348 related articles for article (PubMed ID: 32558674)
1. Pharmacokinetic Variability During Long-Term Therapeutic Drug Monitoring of Valproate, Clobazam, and Levetiracetam in Patients With Dravet Syndrome.
Johannessen Landmark C; Heger K; Lund C; Burns ML; Bjørnvold M; Sætre E; Johannessen SI
Ther Drug Monit; 2020 Oct; 42(5):744-753. PubMed ID: 32558674
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid.
Jullien V; Chhun S; Rey E; Dulac O; Tod M; Chiron C; Pons G
Clin Pharmacokinet; 2015 May; 54(5):527-36. PubMed ID: 25503589
[TBL] [Abstract][Full Text] [Related]
3. A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects.
Morrison G; Crockett J; Blakey G; Sommerville K
Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1009-1031. PubMed ID: 30791225
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability.
Burns ML; Baftiu A; Opdal MS; Johannessen SI; Landmark CJ
Ther Drug Monit; 2016 Jun; 38(3):350-7. PubMed ID: 26751267
[TBL] [Abstract][Full Text] [Related]
5. Impact of Drug Interactions on Clobazam and N-Desmethylclobazam Concentrations in Pediatric Patients With Epilepsy.
Russell GR; Phelps SJ; Shelton CM; Wheless JW
Ther Drug Monit; 2018 Aug; 40(4):452-462. PubMed ID: 29746397
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP2C19 Phenotypes on Clinical Efficacy of Stiripentol in Japanese Patients With Dravet Syndrome.
Yamamoto Y; Takahashi Y; Ikeda H; Imai K; Kagawa Y; Inoue Y
Ther Drug Monit; 2020 Apr; 42(2):302-308. PubMed ID: 31318844
[TBL] [Abstract][Full Text] [Related]
7. Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures.
Klein P; Tolbert D; Gidal BE
Epilepsy Behav; 2019 Oct; 99():106459. PubMed ID: 31519475
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic Variability of Sulthiame: The Impact of Age, Drug-Drug Interactions, and Biochemical Markers of Toxicity in Patients with Epilepsy.
Heger K; Kjeldstadli K; Ring N; Aaberg KM; Kjeldsen SF; Burns ML; Johannessen SI; Johannessen Landmark C
Ther Drug Monit; 2024 Apr; 46(2):237-245. PubMed ID: 38158595
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy.
Peigné S; Chhun S; Tod M; Rey E; Rodrigues C; Chiron C; Pons G; Jullien V
Clin Pharmacokinet; 2018 Jun; 57(6):739-748. PubMed ID: 28819726
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up with therapeutic drug monitoring of antiepileptic drugs in patients with juvenile myoclonic epilepsy.
Johannessen Landmark C; Fløgstad I; Baftiu A; Syvertsen M; Enger U; Koht J; Johannessen SI
Epilepsy Res; 2019 Sep; 155():106148. PubMed ID: 31195184
[TBL] [Abstract][Full Text] [Related]
11. Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy.
Jogamoto T; Yamamoto Y; Fukuda M; Suzuki Y; Imai K; Takahashi Y; Inoue Y; Ohtsuka Y
Epilepsy Res; 2017 Feb; 130():7-12. PubMed ID: 28081475
[TBL] [Abstract][Full Text] [Related]
12. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
Devinsky O; Patel AD; Thiele EA; Wong MH; Appleton R; Harden CL; Greenwood S; Morrison G; Sommerville K;
Neurology; 2018 Apr; 90(14):e1204-e1211. PubMed ID: 29540584
[TBL] [Abstract][Full Text] [Related]
13. Stiripentol in Dravet syndrome: results of a retrospective U.S. study.
Wirrell EC; Laux L; Franz DN; Sullivan J; Saneto RP; Morse RP; Devinsky O; Chugani H; Hernandez A; Hamiwka L; Mikati MA; Valencia I; Le Guern ME; Chancharme L; de Menezes MS
Epilepsia; 2013 Sep; 54(9):1595-604. PubMed ID: 23848835
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan.
Inoue Y; Ohtsuka Y;
Epilepsy Res; 2015 Jul; 113():90-7. PubMed ID: 25986195
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence.
Inoue Y; Ohtsuka Y;
Epilepsy Res; 2014 May; 108(4):725-31. PubMed ID: 24630050
[TBL] [Abstract][Full Text] [Related]
16. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies.
de Leon J; Spina E; Diaz FJ
Ther Drug Monit; 2013 Feb; 35(1):30-47. PubMed ID: 23318278
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic variability of valproate during pregnancy - Implications for the use of therapeutic drug monitoring.
Johannessen Landmark C; Farmen AH; Burns ML; Baftiu A; Lossius MI; Johannessen SI; Tomson T
Epilepsy Res; 2018 Mar; 141():31-37. PubMed ID: 29453075
[TBL] [Abstract][Full Text] [Related]
18. Interactions of clobazam with conventional antiepileptics in children.
Theis JG; Koren G; Daneman R; Sherwin AL; Menzano E; Cortez M; Hwang P
J Child Neurol; 1997 Apr; 12(3):208-13. PubMed ID: 9130097
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.
Johannessen Landmark C; Baftiu A; Tysse I; Valsø B; Larsson PG; Rytter E; Johannessen SI
Ther Drug Monit; 2012 Aug; 34(4):440-5. PubMed ID: 22777154
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic variability of valproate in women of childbearing age.
Johannessen Landmark C; Burns ML; Baftiu A; Farmen AH; Lossius MI; Johannessen SI; Tomson T
Epilepsia; 2017 Oct; 58(10):e142-e146. PubMed ID: 28833045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
